Puma Biotechnology (PBYI) Accumulated Expenses (2011 - 2026)

Puma Biotechnology has reported Accumulated Expenses for 16 years, with the latest figure at $38.4 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 400.5% year-over-year to $38.4 million; the trailing twelve-month figure through Mar 2026 stood at $38.4 million (up 400.5% YoY), and the FY2025 full-year result was $567000.0, down 92.89% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $38.4 million, up from $567000.0 in the prior quarter.
• The five-year high for Accumulated Expenses was $39.0 million in Q2 2024, with the low at $567000.0 in Q4 2025.
• Historically, Accumulated Expenses has averaged $9.8 million across 5 years, with a median of $4.4 million in 2023.
• Annual changes were most pronounced in 2023 — Accumulated Expenses jumped 3587.01% — and 2025, when it tumbled 96.96%.
• Puma Biotechnology's Accumulated Expenses stood at $1.2 million in 2022, then jumped by 255.15% to $4.4 million in 2023, then soared by 82.14% to $8.0 million in 2024, then sank by 92.89% to $567000.0 in 2025, then surged by 6668.61% to $38.4 million in 2026.
• The last three Accumulated Expenses figures came in at $38.4 million (Q1 2026), $567000.0 (Q4 2025), and $5.4 million (Q3 2025), per Business Quant data.